These video briefs feature expert insights on the latest clinical data presented at ACC 2025. Leading cardiologists discuss emerging nonsteroidal mineralocorticoid receptor antagonists (MRAs), their efficacy in heart failure management, and their potential advantages over traditional steroidal MRAs. The series explores key trial findings, safety considerations, and clinical implications for optimizing patient care. Viewers will gain practical knowledge on integrating these novel therapies into clinical practice to improve patient outcomes.
NYHA FC and Finerenone Response: Clinical Trial Insights
Dr. Ostrominski discusses new data from ACC 2025 showing that finerenone improves patient outcomes in HFmrEF/HFpEF, regardless of baseline NYHA class.

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Commercial Support
This activity is supported by an independent educational grant from Bayer AG.
Provider(s)/Educational Partner(s)
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and PACE-CME This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of PACE-CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Overview
These video briefs feature expert insights on the latest clinical data presented at ACC 2025. Leading cardiologists discuss emerging nonsteroidal mineralocorticoid receptor antagonists (MRAs), their efficacy in heart failure management, and their potential advantages over traditional steroidal MRAs. The series explores key trial findings, safety considerations, and clinical implications for optimizing patient care. Viewers will gain practical knowledge on integrating these novel therapies into clinical practice to improve patient outcomes.
Commercial Support
This activity is supported by an independent educational grant from Bayer AG.
Provider(s)/Educational Partner(s)
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and PACE-CME This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of PACE-CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?